DelveInsight’s “Acute Lung Injury Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Acute Lung Injury Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Acute Lung Injury market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Acute Lung Injury: An Overview
Acute lung injury (ALI) is lung inflammation that develops in response to a variety of both pulmonary and generalized acute diseases. Acute lung injury is a disorder of acute inflammation that causes disruption of the lung endothelial and epithelial barriers. The alveolar-capillary membrane is comprised of the microvascular endothelium, interstitium, and alveolar epithelium. Cellular characteristics of ALI include loss of alveolar-capillary membrane integrity, excessive transepithelial neutrophil migration, and release of pro-inflammatory, cytotoxic mediators.
Treatment of acute lung injury is based on both ventilatory and non-ventilatory strategies. To date, the most significant advances in the supportive care of lung injury patients have been associated with improved ventilator management. Several clinical trials have shown that a large number of pharmacologic strategies have not been effective in reducing mortality. Recent advances in the understanding of the pathophysiology of acute lung injury have led to investigations of numerous potential pharmacologic treatments.
Acute Lung Injury: Key Stats
-
As per DelveInsight, the total incident population of Acute Lung Injury (ALI) in the 7MM was 267,981+ in 2020.
-
DelveInsight estimates show a higher incidence of Acute Lung Injury in the United States, with an estimated number of 201,587 cases in 2020.
-
In the 7MM, the percentage of cases of Acute Lung Injury is equal for both genders.
-
As per DelveInsight, the total incident population of ALI in Japan was 10,750+ in 2020.
-
Among the EU-5 countries, Germany had the highest incident population of Acute Lung Injury with 22,272+ cases, followed by Italy, with 12,719+ cases in 2020. On the other hand, Spain had the lowest incident population in 2020.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Acute Lung Injury market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report details the Acute Lung Injury market trend for each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.
Acute Lung Injury Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.
Acute Lung Injury Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acute Lung Injury market or expected to be launched during the study period. The analysis covers Acute Lung Injury market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Acute Lung Injury Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Request for Sample PDF Report – https://www.delveinsight.com/sample-request/acute-lung-injury-market
Acute Lung Injury Therapeutics Analysis
As per DelveInsight’s assessment, more than 50+ key players are globally involved in developing therapies for Acute Lung Injury. Some of the prominent players include –
-
Apeiron Biologics
-
Asklepion Pharmaceuticals
-
Viela Bio
-
ReAlta Life Sciences
-
AFT Pharmaceuticals
-
Roche
-
Implicit Bioscience
-
Altor BioScience Corporation
-
Cantex Pharmaceuticals
-
Chimerix
-
AstraZeneca
-
Mereo BioPharma
-
Apeptico Forschung und Entwicklung GmbH
-
Aevi Genomic Medicine, LLC
-
Theravance Biopharma
-
GlaxoSmithKline
-
Genentech, Inc.
-
Athersys, Inc.
-
Windtree Therapeutics
-
Exvastat Ltd.
-
MediciNova
-
XORTX Therapeutics
-
Radikal Therapeutics
-
Aqualung Theraputics
-
GEn1E Lifesciences, Inc.
-
Angion Biomedica Corp.
-
Qx Therapeutics
-
Trevena, Inc.
And many others
Acute Lung Injury Therapies covered in the report include:
-
APN01
-
TD-0903
-
VIB7734
-
RLS 0071
-
L-citrulline
-
Dociparstat sodium
Get More Detailed Insights Into the Emerging Therapies & Key Companies – https://www.delveinsight.com/sample-request/acute-lung-injury-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Acute Lung Injury Competitive Intelligence Analysis
4. Acute Lung Injury Market Overview at a Glance
5. Acute Lung Injury Disease Background and Overview
6. Acute Lung Injury Patient Journey
7. Acute Lung Injury Epidemiology and Patient Population
8. Acute Lung Injury Treatment Algorithm, Current Treatment, and Medical Practices
9. Acute Lung Injury Unmet Needs
10. Key Endpoints of Acute Lung Injury Treatment
11. Acute Lung Injury Marketed Products
12. Acute Lung Injury Emerging Therapies
13. Acute Lung Injury Seven Major Market Analysis
14. Attribute Analysis
15. Acute Lung Injury Market Outlook (7 major markets)
16. Acute Lung Injury Access and Reimbursement Overview
17. KOL Views on the Acute Lung Injury Market.
18. Acute Lung Injury Market Drivers
19. Acute Lung Injury Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report – https://www.delveinsight.com/sample-request/acute-lung-injury-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Report by DelveInsight
Gastro-Intestinal Bleeding Market
“Gastro-Intestinal Bleeding Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Gastro-Intestinal Bleeding Market size, share, and trends in the 7MM. Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics Market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/